VELCADE has been approved today in the UK for the first-line treatment of Mantle Cell Lymphoma , an aggressive subtype of blood cancers , collectively known as Non-Hodgkin Lymphoma . Recent clinical trial results have shown that patients with previously untreated MCL, who were unsuitable for blood stem-cell transplantation, had an improvement in progression free survival compared to the control arm when treated with bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone .
http://ift.tt/1GjJSiu
http://ift.tt/1GjJSiu
No comments:
Post a Comment